[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"adiposity\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:adiposity":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,50,82,109,137,171,199,226,258,280,301,329,353,378],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":4},"100643285","the-influence-of-obesity-and-insulin-sensitivity-on-reward-processing-and-decision-making-100643285",false,"NCT07638059","The Influence of Obesity and Insulin Sensitivity on Reward Processing and Decision Making","No acronym","Inclusion Criteria:\n\n* 18 to 45 years of age\n* Self-reported weight stable (within 5 lbs) for previous 3 months\n* Not pregnant or planning to become pregnant during study participation\n* Weigh more than 110 lbs (due to blood draws used in study)\n* Residing in Roanoke, VA, area and\u002For willing to attend sessions at the Fralin Biomedical Research Institute\n\nExclusion criteria:\n\n* BMI \\\u003C 18.5 or \\> 40 kg\u002Fm2\n* Hemoglobin A1c \\> 6.4%\n* Fasting blood glucose \\> 126 mg\u002FdL\n* 2-hour blood glucose \\> 200 mg\u002FdL\n* Self-reported current diagnosis of diabetes or other endocrine\u002Fmetabolic disorder\n* Self-reported current inhaled nicotine use\n* Self-reported history of alcohol dependence\n* Self-reported use of medications known to influence study measures (including antiglycemic agents, thyroid medications, etc.)\n* Self-reported neurological or psychological disorder\n* Self-reported claustrophobia or discomfort with mock fMRI training\n* Self-reported history of head injury resulting in loss of consciousness for more than 10 minutes\n* Contraindications to MRI, including pacemaker, aneurysm clip, neurostimulator, cochlear implant, metal in eyes, steel worker, other implants\n* Self-reported previous metabolic\u002Fweight loss surgery\n* Self-reported adherence to special or restrictive diet within the past 3 months (e.g., low-carb, ketogenic, exclusion of food groups\u002Fspecific macronutrients, etc.)\n* Self-reported allergy to ingredient used in the study drinks",true,"ALL","18 Years","45 Years",{"count":21,"type":22},50,"ESTIMATED","INTERVENTIONAL",[25],"NA","Reward learning and decision-making processes, which operate largely outside of conscious control, shape food choices and eating behaviors. Excess adiposity is associated with differences in brain structure and functional connectivity underlying these processes, and insulin resistance, which commonly co-occurs with excess adiposity, has been linked with dopamine signaling that is crucial for these processes. However, whether and how excess adiposity and insulin resistance affect reward learning and decision-making remains poorly understood. This study will address that gap, examining the effects of excess adiposity and insulin resistance, and their interaction, on processes of reward learning and decision-making in food-specific and general contexts.",[28,29,30,31],"Adiposity","Insulin Sensitivity\u002FResistance","Decision-Making","Reward Learning",[33,34,35,36,37],"flavor nutrient learning","insulin sensitivity","adiposity","decision-making","probabilistic learning","NOT_YET_RECRUITING","2026-06-05",{"date":41,"type":42},"2026-06-10","ACTUAL",{"date":44,"type":22},"2026-07-01",{"date":46,"type":22},"2029-07-01",{"name":48,"class":49},"Virginia Polytechnic Institute and State University","OTHER",{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":60,"conditions":61,"keywords":66,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100526005","effect-of-weight-loss-on-intermuscular-adipose-tissue-imat-signaling-100526005","NCT06129110","Effect of Weight Loss on Intermuscular Adipose Tissue (IMAT) Signaling","Inclusion Criteria:\n\n* Generally healthy men and women aged 18-70\n* BMI between 30-40\n* Less than 1 hour of exercise per week\n* Women:\n\n  1. may be pre or post menopausal\n\nExclusion Criteria:\n\n* Type 1 or Type 2 diabetes\n* Thyroid disease\n* History of lung disease\n* Active use of nicotine\n* Severe plasma lipid disorders\n* Taking hormone replacement drugs, blood thinners, or thiazoladinediones\n* Women:\n\n  1. Currently going through menopause or peri-menopause\n  2. Pregnant or breastfeeding\n  3. History of Polycystic Ovary Syndrome","70 Years",{"count":58,"type":22},70,[25],"The goal of this intervention study is to learn about how weight loss impacts molecular signaling of intermuscular adipose tissue (IMAT) in individuals with obesity. The main question it aims to answer is how inflammatory molecules secreted by IMAT promote muscle insulin resistance and inflammation, and how these same molecules are diminished after weight loss. Following screening visits involving body composition measures, blood testing, strength testing, and a thigh muscle biopsy, participants will go through a 12-week dietary intervention for weight loss. After 12 weeks, this will be followed by the same testing and biopsies that were completed before the intervention. Researchers will then compare outcomes of individuals who lost weight to individuals who did not lose weight.",[62,63,64,28,65],"Obesity","Insulin Sensitivity","Muscle Weakness","Insulin Resistance",[67,68,69,70],"IMAT","Intermuscular Adipose Tissue","Weight Loss","Diet","RECRUITING","2026-05-13",{"date":74,"type":42},"2026-05-15",{"date":76,"type":42},"2024-01-31",{"date":78,"type":22},"2028-09-01",{"name":80,"class":49},"University of Colorado, Denver",1,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":88,"minAge":18,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":23,"phases":92,"briefSummary":93,"conditions":94,"keywords":95,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":81},"100557025","redefining-bmi-the-body-mind-and-inflammation-trial-100557025","NCT06532747","Redefining BMI: The Body, Mind, and Inflammation Trial","Inclusion Criteria:\n\n* Ages 18-25 years\n* Body mass index (BMI) 25-50 kg\u002Fm\\^2\n* Female\n\nExclusion Criteria:\n\n* Currently pregnant or lactating\n* Current involvement in a weight loss program or current use of weight loss medication\n* Lost \\>5% of their body weight in the previous 3 months\n* Uncontrolled medical conditions that may pose a safety issue given the recommendations for the diet and unsupervised physical activity\n* Diagnosis of type 2 diabetes and\u002For impaired fasting blood glucose\n* Diagnosis of type 1 diabetes\n* Rheumatologic and gastrointestinal conditions associated with severe systemic inflammation\n* Medical conditions resulting in known perturbations in the hypothalamic-pituitary-adrenal axis\n* Report of a heart condition, chest pain during periods of activity or rest, or loss of consciousness\n* Current or recent (during the past 3 months) use of medications that may impact weight or metabolic function\n* Current or recent (during the past 3 months) use of anti-inflammatory medications\n* Report of diagnosis or history of Anorexia Nervosa or Bulimia Nervosa, or any compensatory behaviors within the previous 3 months\n* Hospitalization for depression or other psychiatric disorder within the past 12 months\n* Uncontrolled bipolar disorder or psychotic disorder\n* Current suicidal intent\n* Planning to move from the area within the study period\n* Unwilling to be randomized to either study condition\n* Unable to read and speak English","FEMALE","25 Years",{"count":91,"type":22},32,[25],"Emerging adulthood (18-25 years of age) is a critical developmental window to promote weight management and cardiometabolic health, particularly for emerging adult women. The primary purpose of this study is to test the preliminary efficacy of the intensive lifestyle intervention for EA women in reducing adiposity, as well as improving biomarkers of inflammation and metabolic risk over 12 months compared with a traditional behavioral weight loss intervention. This treatment program will be tested in emerging adult (EA) women ages 18-25 years old with a BMI of 25-50 kg\u002Fm\\^2.",[62,28],[96,97,98,99],"BMI","Emerging Adult (EA) Women","Lifestyle Intervention","Biomarker Inflammation Improvement","2026-05-05",{"date":102,"type":42},"2026-05-06",{"date":104,"type":42},"2025-09-26",{"date":106,"type":22},"2027-03-03",{"name":108,"class":49},"Virginia Commonwealth University",{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":23,"phases":120,"briefSummary":121,"conditions":122,"keywords":125,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":81},"100558074","glp-1-ra-on-alcohol-consumption-metabolism-and-liver-parameters-in-patients-with-obesity-and-fatty-liver-disease-100558074","NCT06546384","GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease","Effect of Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease","GLP-1 RA","Inclusion Criteria:\n\n* BMI ≥ 35 kg\u002Fm² OR BMI ≥ 28 kg\u002Fm² in the case of weight-related co-morbidities (pre-diabetes or type 2 diabetes mellitus, hypertension, dyslipidemia).\n* Fatty liver disease (steatosis on ultrasound and\u002For CAP value on FS \\> 238 dB\u002Fm)\n* Age 18 - 80 years\n* Alcohol Use Disorder Identification Test-C Score \\>4 (AUDIT-C) Score ≥4 for women and ≥5 for men (as measured from AUDIT-questionnaire distributed in visit 1)\n* Sufficient skills for German or French language (written and spoken)\n* Signed informed consent\n\nExclusion Criteria:\n\n* Active illicit substance use\n* AUDIT-score \\\u003C 5 (males)\u002F 4 (females) (as measured from AUDIT-questionnaire distributed in visit 1)\n* Current treatment with drugs against alcohol dependence (disulfiram, acamprosate, naltrexone, baclofen and nalmefene)\n* Any known contraindication to semaglutide\n* Presence or history of a hepatic or extrahepatic malignancy from the previous 6 months","80 Years",{"count":119,"type":22},64,[25],"There is evidence that alcoholic beverage consumption significantly interacts with food energy intake. Furthermore, there is accumulating evidence showing independent, combined, and modifying effects of alcohol and metabolic factors on the onset and progression of chronic liver disease. Preclinical and clinical data have showed that GLP-1 RA can decrease alcohol consumption, particularly in obese patients. Moreover there is evidence that semaglutide can improve the liver sinusoidal milieu in pre-clinical models of cirrhosis.\n\nIn this study, the investigators aim to assess if patients treated with semaglutide and receiving counselling will achieve a significantly higher alcohol abstinence compared to patients only receiving counselling.",[28,123,124],"Fatty Liver","Alcohol Use Disorder",[126,127],"GLP-1","Semaglutide","2026-02-23",{"date":130,"type":42},"2026-02-25",{"date":132,"type":22},"2026-05-01",{"date":134,"type":22},"2027-04-30",{"name":136,"class":49},"Insel Gruppe AG, University Hospital Bern",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":17,"minAge":145,"maxAge":146,"enrollmentInfo":147,"targetDuration":4,"studyType":23,"phases":149,"briefSummary":150,"conditions":151,"keywords":158,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":81},"100532095","early-life-intervention-in-pediatrics-supported-by-e-health-100532095","NCT06208345","Early Life Intervention in Pediatrics Supported by E-health","Early Life Intervention in Pediatrics Supported by E-health (ELIPSE I): Coaching Parents to Lower Obesity in Children. A Single-blind Randomized Controlled Parallel-group Clinical Trial.","ELIPSE-I","Inclusion Criteria:\n\n* German speaking parents\n* Any ethnic background\u002Frace\n* Children should live\u002Fgrow-up in the same household as the parental participant\n* Children with an age- and sex-matched BMI \\>97 centile according to Swiss national growth charts\n* Children who attend the outpatient weight management clinic at the Division of Pediatric Endocrinology at the University Children's Hospital Bern\n* Signed informed consent form from parent(s)\n\nExclusion Criteria:\n\n* Syndromic obesity\n* Known congenital disease affecting musculo-skeletal, cardiac or pulmonary function\n* Participation in another clinical trial targeting similar objectives","6 Years","12 Years",{"count":148,"type":22},148,[25],"Childhood obesity in early life contributes to the development of specific NCDs, i.e. adult obesity. Unhealthy diet and low level of physical activity are lifestyle risk behaviors associated with chronic, systemic inflammation, which promotes the pathogenesis of NCDs. Early preventive measures to improve lifestyle behavior are of utmost importance. The aim of ELIPSE-I is to assess whether an eHealth application intervention for parents is feasible and efficacious in lowering total energy intake\u002Ftotal energy expenditure (TEI\u002FTEE) ratio in their children with BMI \\>97 centile (ELIPSE-I).",[28,152,153,154,155,156,157],"Childhood Obesity","Adolescent Obesity","Non-communicable Disease","Life Style","Behavior, Eating","Behavior, Health",[28,159,160,161,162],"Children","Adolescents","Prevention","eHealth","2026-02-12",{"date":165,"type":42},"2026-02-18",{"date":167,"type":42},"2024-02-16",{"date":169,"type":22},"2028-12-31",{"name":136,"class":49},{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":177,"enrollmentInfo":178,"targetDuration":4,"studyType":23,"phases":180,"briefSummary":181,"conditions":182,"keywords":185,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":81},"100621296","comparison-of-genotype-based-dietary-counseling-versus-standard-dietary-counseling-on-weight-loss-and-fat-mass-reduction-100621296","NCT07368777","Comparison of Genotype-Based Dietary Counseling Versus Standard Dietary Counseling on Weight Loss and Fat Mass Reduction","Inclusion Criteria:\n\n* Adults aged ≥18 years\n* Body mass index (BMI) ≥25 kg\u002Fm²\n* Greek-speaking (able to read and understand Greek and provide informed consent)\n* Willing and able to participate in dietary counseling and study assessments for the duration of the study\n\nExclusion Criteria:\n\n* Current use of pharmacological treatments for weight loss, including but not limited to GLP-1 receptor agonists, appetite suppressants, or other anti-obesity medications\n* Participation in any structured weight-loss intervention or program within the previous 3 months, including commercial weight-loss programs or medically supervised dietary interventions\n* Use of medications known to significantly affect body weight or body composition, such as systemic corticosteroids, antipsychotic medications, or medications for thyroid disorders\n* Pregnancy or lactation\n* Presence of medical conditions that may affect body weight, metabolism, or nutritional status, including untreated thyroid disease, severe gastrointestinal disorders, or endocrine disorders","65 Years",{"count":179,"type":22},88,[25],"This study aims to compare the effects of genotype-based dietary counseling with standard dietary counseling based on general recommendations on weight loss and reduction of body fat. Participants will receive individualized dietary guidance either informed by genetic information or based on conventional dietary guidelines. Changes in body weight and body composition will be assessed over the course of the intervention.",[183,184,28],"Overweight","Overweight and Obesity",[186,187,188,189],"genotype-based nutrition","dietary counseling","weight loss","nutrigenetics","2026-01-26",{"date":192,"type":42},"2026-01-28",{"date":194,"type":42},"2025-12-15",{"date":196,"type":22},"2027-03",{"name":198,"class":49},"Metropolitan College",{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":16,"sex":17,"minAge":205,"maxAge":146,"enrollmentInfo":206,"targetDuration":4,"studyType":23,"phases":208,"briefSummary":209,"conditions":210,"keywords":214,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":225},"100515529","the-sweet-kids-study-stevia-on-weight-and-energy-effect-over-time-100515529","NCT05992688","The Sweet Kids Study (Stevia on Weight and Energy Effect Over Time)","Inclusion Criteria\n\n* Age 8-12 years\n* Normal weight: BMI percentile ≥5th to \\\u003C85th\n* Excessive weight: BMI percentile ≥ 85th and \\\u003C140% of the 95th percentile or BMI ≥35 to \\\u003C40 kg\u002Fm2\n* Current consumption of sugar sweetened beverages (≥2 times \u002Fwk)\n* Low consumption of non-nutritive sweeteners (≤ 3 time\u002Fwk)\n* Willingness to consume experimental products Exclusion Criteria\n* Children with class 3 obesity (i.e., BMI ≥ 140% of the 95th percentile or BMI ≥ 40.0 kg\u002Fm2)\n* Dislike of experimental beverage taste (assessed at initial visit)\n* Asthma that requires daily use of inhalers to keep symptoms under control.\n* Asthma that requires use of rescue inhalers (e.g., albuterol) \\>2 days per week\n* Exercise induced asthma.\n* Autism spectrum disorder (e.g., Autistic disorder, Rett disorder, Asperger disorder, childhood disintegrative disorder, pervasive developmental disorder not otherwise specified (PDD-NOS).\n* Attention deficit hyperactivity disorder (ADHD) currently under medication.\n* Oppositional defiant disorder (ODD).\n* Epilepsy.\n* Cancer.\n* Chronic kidney disease.\n* Endocrine disorder (e.g., hypothyroidism and growth hormone deficiency).\n* Autoimmune diseases (e.g., lupus, thyroiditis, juvenile idiopathic arthritis)\n* Bleeding disorders (e.g., hemophilia)\n* Chronic infections (e.g., HIV, hepatitis B, hepatitis C).\n* Mental health disorders (e.g., depression and anxiety).\n* Type 2 and type 1 diabetes mellitus.\n* Other pre-existing medical conditions or medications as determined by the investigators to affect the outcomes of interest.\n* If, during the screening or consent process, the parent or child expresses refusal to have blood drawn. However, participants may remain in the study if after initially agreeing to the blood draw and enrolling they change their minds and choose not to allow blood draws or if blood draws are unsuccessful.\n* Dislike of study products assessed at initial visit.\n* Fasting glucose ≥126 mg\u002Fdl at enrollment.\n* Fasting A1C ≥6.5% at enrollment\n* Less than 2 months since completion of antibiotics","8 Years",{"count":207,"type":22},150,[25],"This is an 8 to14-week three-arm randomized controlled in children 8 to 12 years old.\n\nThe main purpose of the study is to evaluate if stevia has benefits for weight control and metabolic function relative to caloric sweeteners, and whether it provides benefits in this regard similar to water.",[28,63,211,212,213],"Weight Gain","Blood Pressure","Lipoproteins",[215],"Cardiometabolic health","2025-12-16",{"date":218,"type":42},"2025-12-22",{"date":220,"type":42},"2023-09-19",{"date":222,"type":22},"2026-11-30",{"name":224,"class":49},"Arkansas Children's Hospital Research Institute",2,{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":232,"eligibilityCriteria":233,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":234,"targetDuration":4,"studyType":236,"phases":4,"briefSummary":237,"conditions":238,"keywords":244,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":81},"100426841","effects-of-cross-sex-hormone-therapy-on-eating-behavior-metabolism-energy-balance-and-cardiovascular-system-100426841","NCT04838249","Effects of Cross-sex Hormone Therapy on Eating Behavior, Metabolism, Energy Balance and Cardiovascular System","Investigation of the Effects of Testosterone and Estrogen on Eating Behavior, Metabolism, Energy Balance and Cardiovascular System in Transsexual Patients Undergoing Cross-sex Hormone Therapy","HHS","Inclusion Criteria:\n\n* transsexual patients undergoing cross-sex hormone therapy versus controls\n* able to give informed consent, if \\\u003C18 years from all legal guardians\n* only for part B (patients will participate in all other study parts): weight stable (± 5%) for last 3 months, BMI ≤ 30 kg\u002Fm2\n\nExclusion Criteria:\n\n* severe medical impairments (e.g., uncontrolled cardiovascular disease, severe heart failure, uncontrolled hypertension, cerebral insult, active malign disease, etc.)\n* self-initiated cross-sex hormone therapy before study start only for part B (patients will participate in all other study parts): Insufficiently controlled endocrine disorders (Cushing's disease, other uncontrolled pituitary disorders, uncontrolled hypothyroidism, hyperthyroidism, etc.)\n* Chronic pulmonary disorders, including chronic obstructive pulmonary disease that would limit ability to follow the protocol (investigator judgment) and obstructive sleep apnea syndrome; only subjects with mild or exercise-induced asthma on no medications or on beta-adrenergic agonists only will be allowed to enter the study (provided use of these agents is not required for 1 week before\n* Diagnosed gastrointestinal diseases, including inflammatory bowel diseases (e.g. Crohn's disease and ulcerative colitis), malabsorption syndromes (e.g. celiac disease), gastric ulcer (active); only subjects with gastro-esophageal reflux will be allowed to enter the study entry).\n* History of HIV infection or ongoing chronic infection (such as tuberculosis)\n* only for part D (patients will participate in all other study parts): Contraindication against performance of an MRI scan (i.e., presence of metal in body, tattoos in head\u002Fneck region, claustrophobia etc.)",{"count":235,"type":22},80,"OBSERVATIONAL","Current study aims to characterize five highly interconnected physiological systems in patients undergoing cross-sex hormone therapy - namely glucose and lipid metabolism, energy balance, eating behavior, functional brain networks involved in the regulation of eating behavior and the cardiovascular system - to gain novel insights into the effects of sex hormones on the human body. Gathered information will help to identify pathophysiological mechanisms for the development of overeating\u002Fobesity, insulin resistance, and cardiovascular disease. Secondarily, the relationships between the gut and oral microbiomes and metabolomes and circulating bacterial signatures will be investigated in relation to the other pervasive physiological systems.\n\nCurrent study is an observational study. The decision if the patient's request for cross-sex hormone therapy can complied with (i.e., if cross-sex hormone therapy is medically indicated) is made prior to the first contact with the study center and with the outpatients clinic for Endocrinology at the University Hospital in Leipzig. Decision ifor treatment is made according to national and international guidelines. Treatment of study participants with testosterone and estradiol\u002Fantiandrogens is not affected by the study. During the course of the study no invasive interventions are being performed.",[239,240,28,241,242,243],"Transsexualism","Transgenderism","Eating Behavior","Arterial Stiffness","Microangiopathy",[239,245,246,247,28,248],"Energy expenditure","Energy balance","Eating behavior","Cardiovascular disease","2025-11-27",{"date":251,"type":42},"2025-12-05",{"date":253,"type":42},"2021-05-05",{"date":255,"type":22},"2026-05",{"name":257,"class":49},"University of Leipzig",{"id":259,"slug":260,"hasResults":11,"nctId":261,"briefTitle":262,"officialTitle":262,"acronym":4,"eligibilityCriteria":263,"healthyVolunteers":16,"sex":88,"minAge":19,"maxAge":56,"enrollmentInfo":264,"targetDuration":4,"studyType":23,"phases":266,"briefSummary":267,"conditions":268,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":81},"100552723","the-influence-of-chardonnay-marc-intake-on-gut-and-cardiometabolic-health-100552723","NCT06476795","The Influence of Chardonnay Marc Intake on Gut and Cardiometabolic Health","Inclusion Criteria:\n\n* Postmenopausal female, with a cessation of menses for at least 2 years\n* 45-70 years of age\n* BMI 25- 49.9 kg\u002Fm2\n* Fasting triglycerides \\> 120 mg\u002FdL\n* Subject is willing and able to comply with the study protocols and procedures.\n\nExclusion Criteria:\n\n* Self-reported use of daily anticoagulation agents including aspirin, NSAIDs\n* Prescription medications and supplements, except for a 6 month stable dose of thyroid medications\n* Vegan, Vegetarians, food faddists or those consuming a non-traditional diet\n* Fruit consumption ≥ 3 cups\u002Fday\n* Vegetable consumption ≥ 4 cups\u002Fday\n* Coffee\u002Ftea ≥ 3 cups\u002Fday\n* Dark chocolate ≥ 3 oz\u002Fday\n* Self-reported restriction of physical activity due to a chronic health condition\n* Self-reported chronic\u002Froutine high intensity exercise\n* Blood pressure ≥ 140\u002F90 mm Hg\n* Self-reported renal or liver disease\n* Self-reported heart disease, which includes cardiovascular events and stroke, diabetes\n* Peripheral artery disease Raynaud's syndrome or disease\n* Inability to properly place or wear the PAT probes or abnormal measurements on pre-screening PAT\n* Self-reported cancer within past 5 years\n* Self-reported gastrointestinal disorders, apart from appendix removal\n* Unwillingness to stop any supplement use, including herbal, plant or botanical, fish oil, oil supplements six weeks prior to study enrollment.\n* Indications of substance or alcohol abuse within the last 3 years\n* All forms of smoking (e.g. vaping, cigarette, cannabis)\n* Current enrollee in a clinical research study.",{"count":265,"type":22},5,[25],"Recently a dietary recommendation of 400 - 600 mg\u002F day has been proposed for the reduced risk of developing cardiovascular disease. Dietary flavanols can be obtained from the intake of foods such as tea, cocoa, wine, berries and apples. Incorporating Chardonnay Marc (the skins and seeds of Chardonnay grapes) into the diet can be an additional source of dietary flavanols. Like other flavanol-rich foods, Chardonnay Marc provides fiber and polysaccharides that may benefit gut health. This study seeks pilot data on the impact of the daily incorporation of Chardonnay Marc powder into the diet on markers of gut and cardiometabolic health.",[269,28,270],"Cardiovascular Diseases","Cardiometabolic Syndrome","2025-07-07",{"date":273,"type":42},"2025-07-10",{"date":275,"type":42},"2024-06-01",{"date":277,"type":22},"2026-06",{"name":279,"class":49},"University of California, Davis",{"id":281,"slug":282,"hasResults":11,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":286,"eligibilityCriteria":287,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":288,"targetDuration":4,"studyType":236,"phases":4,"briefSummary":289,"conditions":290,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":81},"100529608","visceral-adiposity-vagal-tone-and-food-preferences-a-pilot-study-100529608","NCT06175988","Visceral Adiposity, Vagal Tone and Food Preferences: a Pilot Study","Adiposité Viscérale, Tonus Vagal Et Préférences Alimentaires : Une Étude Pilote","ObVague","Inclusion Criteria:\n\n* Have a BMI between 18.5 and 35 kg\u002Fm²;\n* French-speaking;\n* Be able to travel to the Research Center of the Institut Universitaire de Cardiologie et Pneumologie de Québec for an investigative visit.\n\nExclusion Criteria:\n\n* Smokers ;\n* Women who know they are pregnant, breastfeeding or menopausal;\n* Who have been diagnosed with type I or type II diabetes;\n* Having undergone bariatric surgery or obesity medication (GLP1 analogue, naltrexon-bupropion combination, etc.);\n* Presenting an allergy or intolerance to one of the products used in the sensory tests (taste test: sucrose, sodium chloride, citric acid, quinine hydrochloride dihydrate; olfactory test: citrus, lemongrass, cinnamon, mint, peppermint, banana, anise, turpentine, garlic, coffee, apple, clove, pineapple, rose, geranium, eucalyptus, wormwood, fennel, caraway, leather, n-butanol, linalool, pyridine, diethyl phthalate, propylene glycol);\n* Have a history of pathologies which, in the investigator's opinion, could interfere with the study criteria, such as ENT, neurological, upper digestive or cardiac pathologies;\n* Receiving long-term pharmacological treatment, in particular antidepressants, antipsychotics, benzodiazepines, beta-blockers, etc. ;\n* Presenting or having presented in the last 6 months a thymic episode such as depression, bipolar disorder, etc. ;\n* Wearing a cardiostimulator (pacemaker);\n* Minors or adults under guardianship.",{"count":58,"type":22},"Food preferences are defined by a number of measurable parameters, such as per se food choices, sensitivity of taste and olfactory sensory perceptions, hedonic appreciation of foods (\"liking\") and motivation to consume them (\"wanting\"). These food preferences are fundamental to the quality of food intake, and are therefore a key factor influencing weight loss or maintenance of a stable weight. Obesity is also associated with reduced sensory sensitivity to taste and smell, as well as disturbances in the responses of the food reward system.\n\nHowever, the internal, or physiological, mechanisms impacting these food preferences are still poorly understood. To date, several studies seem to point to the role of body composition, in particular visceral adiposity, or adiposity surrounding the digestive organs. Indeed, a high level of visceral adiposity is associated with the onset of numerous cardiometabolic disorders, but also with altered sensory perceptions.\n\nThis relationship could be mediated by the vagus nerve, which connects the digestive organs to the brain, enabling the perception of internal signals sent by the body, such as feelings of hunger or satiety. Low vagal activity is associated not only with abdominal obesity, but also with reduced sensory sensitivity to taste and smell, and changes in food choices in favor of energy-dense foods (rich in fats and\u002For sugars). Electrical stimulation of the vagus nerve is now recognized as a possible treatment for morbid obesity in the USA, but the mechanisms leading to the expected weight loss are still debated. Similarly, an increase in vagal tone has been found in patients who have undergone bariatric surgery for the treatment of severe complicated to morbid obesity, in parallel with sensory disturbances.\n\nThe overall aim of this project is to explore and confirm the relationship between visceral adiposity and various food preference parameters, such as olfactory and gustatory perceptions and reward system responses, involving liking and wanting certain foods and associated behaviors. This project also aims to shed light on the possible mediation of the vagus nerve in this relationship.",[28,291,241],"Food Preferences","2024-10-07",{"date":294,"type":42},"2024-10-09",{"date":296,"type":42},"2023-12-11",{"date":298,"type":22},"2025-12-30",{"name":300,"class":49},"Laval University",{"id":302,"slug":303,"hasResults":11,"nctId":304,"briefTitle":305,"officialTitle":305,"acronym":306,"eligibilityCriteria":307,"healthyVolunteers":16,"sex":88,"minAge":308,"maxAge":19,"enrollmentInfo":309,"targetDuration":4,"studyType":23,"phases":311,"briefSummary":313,"conditions":314,"keywords":318,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":325,"completionDateStruct":326,"leadSponsor":328,"locationsCount":81},"100536442","phase-4-cardiometabolic-consequences-of-the-loss-of-ovarian-function-100536442","NCT06264882","Cardiometabolic Consequences of the Loss of Ovarian Function","LILAC","Inclusion Criteria:\n\n* Age criteria of 20-45 years: the investigators are determining the effects of ovarian suppression on adiposity and vascular in premenopausal women;\n* Premenopausal defined as normal menstrual cycle function defined as no more than 1 missed cycle in the previous year: irregular menstrual or missed menstrual cycles could indicate that women are anovulatory and\u002For perimenopause;\n* Not pregnant or planning to become pregnant;\n* Not lactating in the last 3 months;\n* Serum FSH \\\u003C10 IU\u002FL measured during days 1-10 of the menstrual cycle: to ensure the woman is premenopausal and not perimenopausal;\n* Not on hormonal contraception in the last 3 months;\n* Sedentary or recreationally active (\\\u003C2 days\u002Fwk vigorous exercise);\n* No use of medications that might influence vascular function (i.e., antihypertensives, lipid lowering medications, blood thinners);\n* No use of antioxidant supplements or chronic NSAIDs or be willing to go off them for 4 weeks prior to enrollment in the study;\n\nExclusion Criteria:\n\n* Diabetic or fasted glucose \\>126 mg\u002FdL;\n* Body mass index (BMI) \\>35 kg\u002Fm2;\n* Weight change \\>5 kg in the last 3 months;\n* Use of glucocorticoids (inhaled, oral, topical) or drugs that affect glucocorticoid metabolism (e.g., ketoconazole) in the last 3 months;\n* Excess alcohol consumption, defined as \\>14 drinks per week by self-report;\n* Known hypersensitivity to study medications;\n* Depressive symptoms, defined as a CES-D score \\>16;\n* Resting blood pressure \\>150\u002F90 mmHg;\n* Preexisting or active cardiac, renal, or hepatic disease: past or current history of these diseases or conditions;\n* Active or chronic infection: inflammation associated with active or chronic infections impair vascular function;\n* Thyroid dysfunction, defined as an ultrasensitive TSH \\\u003C0.5 or \\>5.0 mU\u002FL; volunteers with abnormal TSH values will be reconsidered for participation in the study after follow-up evaluation by the PCP with initiation or adjustment of thyroid hormone replacement;\n* Smoking or Tobacco use within the previous 12 months;\n* Severe low bone mass or osteoporosis, defined as a hip or lumbar spine T-score \\\u003C-2.0: safety reasons, women who are randomized to the ovarian suppression plus placebo group could see a decrease in bone mineral density due to the suppression of estrogen;\n* History of venous thromboembolic event (VTE): safety reasons, estradiol therapy can increase the risk of VTE;\n* History of breast cancer or other estrogen-dependent neoplasm: estradiol therapy is contraindicated;","20 Years",{"count":310,"type":22},100,[312],"PHASE4","The menopause transition is associated with a decrease in artery health and an increased risk for weight gain in storing fat in the stomach area which may increase the risk for heart disease. The purpose of this research is to study how the decrease in estrogen at menopause changes artery health and fat gain, and risk of disease in women as they age. The first aim in this study will determine whether short term and long term low estrogen levels in premenopausal women decreases artery function and whether this is related to an increase in fat in the stomach area. The second aim will determine whether the changes in artery health and body fat are related to changes in a pathway that breaks down an important amino acid called tryptophan. This pathway is thought to play a role in regulating the aging process. Therefore, the investigators will determine whether the decrease in artery health and the increase in body fat in the stomach region with low estrogen is related to changes in this pathway in the blood, in vascular cells and fat tissue. Because estrogen levels fluctuate in premenopausal women, the investigators will use an approach (intervention) that controls estrogen levels to address these aims. The investigators will use a medication that is typically used to treat endometriosis or uterine fibroids to lower estrogen levels and an estrogen patch to increase estrogen in some women. Some women will receive a patch that has no estrogen (called a placebo patch). The intervention period will be 20 weeks. The study will provide us with new knowledge on how low estrogen with menopause affects artery health and fat gain estrogen.",[315,316,317,28],"Menopause","Estrogen Deficiency","Aging",[319,320,321],"Vascular biology","Women's health","Women","2024-06-18",{"date":324,"type":42},"2024-06-20",{"date":275,"type":42},{"date":327,"type":22},"2028-08-31",{"name":80,"class":49},{"id":330,"slug":331,"hasResults":11,"nctId":332,"briefTitle":333,"officialTitle":333,"acronym":4,"eligibilityCriteria":334,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":335,"targetDuration":4,"studyType":236,"phases":4,"briefSummary":337,"conditions":338,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":345,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":351,"locationsCount":4},"100541207","neuroendocrine-mechanisms-in-adiposity-an-integrated-approach-to-the-characterization-of-potential-pharmacological-novel-targets-based-on-experimental-and-clinical-models-100541207","NCT06326853","Neuroendocrine Mechanisms in Adiposity: An Integrated Approach to the Characterization of Potential Pharmacological Novel Targets Based on Experimental and Clinical Models","Inclusion Criteria:\n\nObese patients affected and not by hypothalamic-pituitary diseases\n\nExclusion Criteria:\n\n1. Minor subjects;\n2. Pregnant and\u002For breastfeeding women;\n3. Patients suffering from states of primary and\u002For acquired immunodeficiencies, and\u002For serious impairment of general clinical conditions (e.g. metastatic neoplasms; immunosuppressive therapies; worsening\u002Freacerbated\u002Fcompensated chronic pathologies);\n4. Patients unable to understand and sign the Informed Consent.",{"count":336,"type":22},200,"The goal of this observational study is to evaluate, retrospectively and prospectively, the effect of different hormonal and neuropeptide dysfunctions on the body composition of patients suffering from hypothalamic-pituitary pathologies, and to evaluate the potential beneficial effect of surgical and medical treatments with agonists and antagonists of hypothalamic neuropeptides, currently available, on the development and treatment of adiposity and negative cross-talk between adiposity and muscle\u002Fbone tissue",[339,28,340,341,342,343],"Endocrine Disorders","Pituitary Adenoma","Cushing Syndrome","Acromegaly","Hypopituitarism","2024-06-10",{"date":346,"type":42},"2024-06-11",{"date":348,"type":22},"2024-07",{"date":350,"type":22},"2026-12",{"name":352,"class":49},"IRCCS San Raffaele",{"id":354,"slug":355,"hasResults":11,"nctId":356,"briefTitle":357,"officialTitle":358,"acronym":359,"eligibilityCriteria":360,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":177,"enrollmentInfo":361,"targetDuration":4,"studyType":23,"phases":363,"briefSummary":364,"conditions":365,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":370,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":376,"locationsCount":81},"100513186","short-term-fat-overfeeding-on-the-effects-of-liver-metabolism-100513186","NCT05962190","Short-term Fat Overfeeding on the Effects of Liver Metabolism","The Effect of Short-term Overconsumption of Specific Dietary Nutrients on Liver and Adipose Tissue Metabolism.","FOS","Inclusion Criteria:\n\n* The participant is willing and able to give informed consent for participation in the study.\n* Male or Female, aged ≥18 or ≤65 years.\n* Body Mass Index ≥19 ≤35 kg\u002Fm2\n* No medical condition or relevant drug therapy that is known to affect liver or adipose tissue metabolism.\n* Weight stable for the previous 3 months\n\nExclusion Criteria:\n\n* The participant is unwilling or unable to give informed consent for participation in the study. - Aged ≤18 or ≥65 years\n* Body Mass Index ≤19 or ≥35kg\u002Fm2\n* Blood haemoglobin \\\u003C135mg\u002FdL for men and \\\u003C120mg\u002FdL for women\n* Donated (or lost) ≥250 ml of blood in the previous two months.\n* On a weight loss diet or have decreased their body weight by \\>5% in the previous 3 months.\n* Have increased their body weight by \\>5% in the previous 3 months.\n* Any metabolic condition or relevant drug therapy\n* Current smoker\n* History of alcoholism or a greater than recommended alcohol intake (\\>30 g of alcohol daily for men and \\>20 g of alcohol daily for women)\n* Haemorrhagic disorders\n* Anticoagulant treatment\n* History of albumin allergy\n* Pregnant or nursing mothers\n* Women prescribed any contraceptive agent or device including oral contraceptives, hormone replacement therapy (HRT) or who have used these within the last 12 months History of severe claustrophobia\n* Presence of metallic implants, pacemakers, or are unwilling to remove any piercings\n* History of an eating disorder or any other psychological condition that may affect the participant's ability to adhere to study intervention\u002Fexperimental diets.",{"count":362,"type":22},26,[25],"Despite work showing the overconsumption of saturated fatty acids (SFA) to be metabolically deleterious, debate continues about whether there is a link between SFA and cardiovascular disease risk. To explore this, we are undertaking a human in vivo parallel-design study, comparing two isocaloric high-fat diets; one enriched with SFA and the other enriched with unsaturated fatty acids (UFAs), to determine the impact of dietary fat composition on postprandial metabolism, liver fat, cardiac fat and cardiac function.",[366,367,368,28],"Liver Fat","Cardiac Function","Lipid Disorder","2023-07-18",{"date":371,"type":42},"2023-07-27",{"date":373,"type":42},"2023-02-15",{"date":375,"type":22},"2028-02",{"name":377,"class":49},"University of Oxford",{"id":379,"slug":380,"hasResults":11,"nctId":381,"briefTitle":382,"officialTitle":382,"acronym":383,"eligibilityCriteria":384,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":385,"enrollmentInfo":386,"targetDuration":308,"studyType":236,"phases":4,"briefSummary":388,"conditions":389,"keywords":392,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":394,"lastUpdatePostDateStruct":395,"startDateStruct":397,"completionDateStruct":399,"leadSponsor":401,"locationsCount":81},"100464191","diabetes-registry-graz-for-biomarker-research-100464191","NCT05324488","Diabetes Registry Graz for Biomarker Research","GIRO","Inclusion Criteria:\n\n* 18 - 99 years\n* Informed consent has to be given in written form\n* At least one of the following diseases:\n* Type 1 diabetes\n* Type 2 diabetes\n* Type 3 diabetes\n* Maturity onset diabetes of young (MODY)\n* Late onset diabetes of the adult (LADA)\n* Adipositas (BMI \\> 30kg\u002Fm2)\n* Lipid metabolism disorder\n\nExclusion Criteria:\n\n* No written informed consent\n* No willingness to participate in this registry","99 Years",{"count":387,"type":22},2000,"The Diabetes registry for biomarker research Graz is a prospective cohort-study including subjects with type 1 and type 2 diabetes, rare types of diabetes, obesity and dyslipidemia, aiming to collect data, blood and urine samples of all subjects on an annual basis.",[390,391,28],"Type1diabetes","Type 2 Diabetes",[393],"cohort study","2023-07-06",{"date":396,"type":42},"2023-07-07",{"date":398,"type":42},"2015-10-21",{"date":400,"type":22},"2035-02-01",{"name":402,"class":49},"Medical University of Graz"]